Committees

ISCT Process Development & Manufacturing Committee

Charter

The Process Development & Manufacturing Committee strives to:

  • Establish and communicate best practices in process development & manufacturing as it relates to therapeutic cell-based products
  • Assess emerging cell processing technologies and forecast their impact on the commercialization process.
  • Discuss critical product development regional regulatory considerations
Topics of interest to the PDM include, but are not limited to:
  • Cryopreservation
  • Particulates
  • Scale up & out challenges
  • Automation
  • Software & Analytics
  • Supply chain management

Ideal Member Profile

  • Individual: Manufacturing or technical process development managers, engineers, and those intimately involved in the everyday challenges of product development.
  • Company: CGT enablers involved in developing equipment and devices, CDMOs, supply chain logistics and who provide software and analytic software.

PDM Committee Working Groups

New to the PDM Committee in 2022 are topic-focused working groups. The working groups were established to provide individuals of the PDM the opportunity to dive deeper into specific manufacturing modules. 

The 2022 Committee

Headshot of Dominic Clarke

Co-Chair

Dominic Clarke, PhD

Discovery Life Sciences
United States

Headshot of John Fink

Chair

John Fink, MBA

Perkin Elmer
United States

Sasha Aleksic, MSc
FUJIFILM Irvine Scientific
United States

Julie Allickson, PhD, MSc, MT(ASCP)
Mayo Clinic
United States

Dirk Balshüsemann
Miltenyi
Germany

Cenk Sumen 
MaxCyte 
United States

Mark Hession 
Grifols
Ireland

Delphine Connan
Cell Matters
Belgium

Ina Bergman
G-CON Manufacturing 
United States

Hiroko Hanzawa

Hitachi
Japan

Christopher Bravery, PhD
Advanced Biologicals Ltd.
United Kingdom

Sonia Bulsara
Cytiva
United States

Emmanuelle Cameau

Pall Corporation
Europe

Ryan Smigiel 
G-CON Manufacturing
United States

Lindsay Davies
NextCell Pharma
Netherlands

Stephanie Davies
Valita Cell
Ireland

Mike Delahaye
AstraZeneca
Sweden

Nisha Durand, PhD
Mayo Clinic
United States

Shannon Eaker, PhD

XCell
United States

Maya Furstenau-Sharp, PhD
Sartorius-Stedim Biotech
Germany

Jeff Gilmore
cGMPnow
United States

Isaac Godfroy

Athersys
United States

Volker Huppert
Glycostem Therapeutics B.v.
Netherlands

Robert Jones
Cryoport
United Kingdom

Anne-Sophie Leburn
Bone Therapeutics
Belgium

Ru Li
West Pharmaceutical Sciences
United States

Matthew Marsh
Minaris
United States

Charlotte Morgan
Regeneus
Australia

Daria Marsh

Catapult
United Kingdom

Sam Molina, PhD
West Pharmaceutical Services
United States

Lisa O'Flynn
Avectas
Ireland

Behman Ahmadian Baghbaderani
Lonza
United States

Steve Oh, PhD
ASTAR
Singapore

Alicia Furr

WL Gore
United States

Ta-Chun Hang

Kytopen
United States 

Jean-Sébastien Parisse, MBA
Aseptic Technologies
Belgium

Sebastian Rieck 
ViaCyte
United States

Janet Rothberg
CCRM
Canada

Robert Sassa

WL Gore & Associates
United States

Brianna Schoen, PhD

HemaCare, A Charles River Company
United States

Michael Scott, PhD
Novo Nordisk
United States

Dalip Sethi
Terumo
United States

Quentin Vicard

Ori Biotech
United States

Daria Popova

Catapult
United States

John Tomtishen

Cellares
United States

Tim Tripp

Be The Match
United States

Joe Valdez

Berkeley Lights
United States

Robert Waters

Santen SA
United States

Sean Werner

BioLife/Sexton
United States

Bastian Westbomke

Arvato
United States

Yiyang Xu

Berkeley Lights
United States

Ezequiel Ztylberberg

Akron Biotech
United States

Fernanda Masri

Catapult
United Kingdom

Pete Makowenskyj

G-CON Manufacturing
United States 

Carol Houts 

Germfree
United States

Steven Binninger 
Autolomous
United Kingdom

Yuki Kato Maves
All Cells 
United States